GBA Presents: RADIO SAVANT-!

Discussion in 'Stocks' started by stonedinvestor, May 13, 2022.





  1. VZ I used Berry from the late $40's and got out in the $58 area.

    It had a nice run now what? I see the cup with a handle and if you back out there is a huge
    cup with a handle as well... Double cups?

    It is a name perhaps best viewed from the sidelines until they report.But a move eventually to $70 is in the cards.

    The sector is still strong. Packaging multiples are well off their lows relative to the S&P, but remain at a discount to pre-pandemic levels.~si
     
    #13281     Feb 1, 2023
  2. 700 rain just now RAIN Rain Oncology Inc.

    $9.440.46 (+5.12%)2:59 PM 02/01/23
     
    #13282     Feb 1, 2023
    vanzandt likes this.
  3. A) Never got my 2nd email had to just call him.!

    B) He did spot an large insider buy of $1 mil dollars worth in the $8 range.

    C) I really like the chart

    D) Fire side Chat next week who has a fire side chat with bad or boring news?

    E) Recent upgrades street likes their prospects.

    f) Near 40% pullback from recent move.

    CHILDREN DANCE IN THE RAIN WITH ME!
     
    #13283     Feb 1, 2023
  4. vanzandt

    vanzandt

    I think you said the same thing when I brought STLD to GBA at $50 a year or so ago.
    :p
     
    #13284     Feb 1, 2023
  5. BOND YIELDS HAVE SLIPPED KICKING OFF BIO-------

    Rain Oncology resumed with a buy at Roth Capital on liposarcoma candidate milademetan

    Jan. 31, 2023 10:48 AM ET Rain Oncology Inc. (RAIN)

    • Roth Capital has resumed coverage of Rain Oncology (NASDAQ:RAIN) with a buy rating saying that the company's lead candidate, milademetan for liposarcoma, has a positive risk/reward setup in advance of a Q1 data readout
    • The firm has a price target of $21 (~117% upside based on Monday's close).
    • Analyst Kumaraguru Raja noted that milademetan has its biggest potential in cancers where MDM2 and p53 are key drivers. MDM2 is an oncogene that modulates p53, a tumor suppressor.
    • Raja added that preclinical data shows that MDM2 could be a target for inflammatory and autoimmune diseases as well.
     
    #13285     Feb 1, 2023


  6. YIKES! STLD IS SUCH A MONSTER. I still have some in 1 acct but I blew out everything. Mistake. I guess they are similar in that they are commodities in a way and have competition and trying to go green etc. They are similar. I like BERY's management.

    STLD Steel Dynamics, Inc.

    $124.85 4.21 (+3.49%)3:15 PM 02/01/23
     
    #13286     Feb 1, 2023
  7. KEEP THEM EMAILS COMING!!!!!

    HERE WE GO MAC...! GET READY TO GET RICH!!!!!!!

    Expedia Group, Inc. (EXPE)
    NasdaqGS - NasdaqGS Real Time Price.
    117.89+3.59 (+3.14%)
    As of 03:35PM EST.
     
    #13287     Feb 1, 2023
    mac likes this.
  8. Those following along with Rain Therapeutics Inc. (NASDAQ:RAIN) will no doubt be intrigued by the recent purchase of shares by Franklin Berger, lead Independent Director of the company, who spent a stonking US$988k on stock at an average price of US$8.10. Aside from being a solid chunk in its own right, the deft move also saw their holding increase by some 14%.

    Rain Therapeutics Insider Transactions Over The Last Year
    In fact, the recent purchase by Franklin Berger was the biggest purchase of Rain Therapeutics shares made by an insider individual in the last twelve months,
     
    #13288     Feb 1, 2023
  9. Powell 'can finally say' disinflation process has started, especially in goods
     
    #13289     Feb 1, 2023
  10. Palantir Technologies call volume above normal and directionally bullish

    AGAIN!
     
    #13290     Feb 1, 2023